Press Releases

Date Title  
Toggle Summary Natera Appoints Rowan Chapman to its Board of Directors
SAN CARLOS, Calif. , Aug. 29, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has appointed Rowan Chapman , Ph.D., to its board of directors, effective August 15, 2019 . "We are extremely pleased to welcome Dr.
Toggle Summary Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference
SAN CARLOS, Calif. , Aug. 28, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Baird 2019 Global Healthcare Conference at the InterContinental New York Barclay hotel in New York City on Wednesday,
Toggle Summary Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer
First step towards reimbursement and adoption of MRD testing in solid tumors SAN CARLOS, Calif. , Aug. 22, 2019 /PRNewswire/ -- Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage determination (LCD)
Toggle Summary Panorama NIPT Achieves 2 Million Test Milestone
SAN CARLOS, Calif. , Aug. 22, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) , a global leader in cell-free DNA testing, today announced that it has now processed more than two million Panorama ® non-invasive prenatal tests (NIPT). Approximately 2,000 Panorama tests are processed each working
Toggle Summary Natera Reports Second Quarter 2019 Financial Results
SAN CARLOS, Calif. , Aug. 7, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for its second quarter ended June 30, 2019 and provided an update on recent business progress.
Toggle Summary Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies
100% Accuracy in Detecting Zygosity Enables Earlier Risk Stratification for Serious Perinatal Complications SAN CARLOS, Calif. , Aug. 5, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) , a global leader in cell-free DNA testing, today announced results of a prospective validation study published
Toggle Summary Natera Announces Second Quarter 2019 Earnings Conference Call
SAN CARLOS, Calif. , July 31, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2019 , after the market close on August 7, 2019 .
Toggle Summary New ProActive™ Study From Natera Will Test for Rejection in 3,000 Kidney Transplant Recipients
Study will evaluate improved clinical outcomes in patients using the Prospera™ dd-cfDNA test SAN CARLOS, Calif. , June 24, 2019 /PRNewswire/ --   Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a nationwide registry study for kidney transplant recipients
Toggle Summary Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness SAN CARLOS, Calif. , June 3, 2019 /PRNewswire/ -- A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the
Toggle Summary Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test
Represents Major Commercialization Milestone SAN CARLOS, Calif. , May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California -based laboratories, has posted a favorable draft local coverage determination (LCD) for use of Natera 's Prospera™ test to assess

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.